MDT

96.14

-0.57%↓

136.19

-1%↓

VEEV

223.11

-0.69%↓

HQY

91.51

-0.5%↓

PHR.US

16.9

-0.59%↓

MDT

96.14

-0.57%↓

136.19

-1%↓

VEEV

223.11

-0.69%↓

HQY

91.51

-0.5%↓

PHR.US

16.9

-0.59%↓

MDT

96.14

-0.57%↓

136.19

-1%↓

VEEV

223.11

-0.69%↓

HQY

91.51

-0.5%↓

PHR.US

16.9

-0.59%↓

MDT

96.14

-0.57%↓

136.19

-1%↓

VEEV

223.11

-0.69%↓

HQY

91.51

-0.5%↓

PHR.US

16.9

-0.59%↓

MDT

96.14

-0.57%↓

136.19

-1%↓

VEEV

223.11

-0.69%↓

HQY

91.51

-0.5%↓

PHR.US

16.9

-0.59%↓

Начало・Списък с акции・Amphastar Pharmaceuticals Inc

Amphastar Pharmaceuticals Inc

Затворен

СекторЗдравеопазване

26.69 -0.63

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

26.55

Максимум

27.01

Ключови измерители
By Trading Economics
Приходи	-14M 17M
Продажби	17M 192M
P/E Средно за сектора	11.854 88.032
EPS	0.93
Марж на печалбата	9.044
Служители	2,028
EBITDA	-20M 42M

Препоръки
By TipRanks
Препоръки	Купи
12-месечна прогноза	+13.89% upside

Пазарни показатели
By TradingEconomics
Пазарна капитализация	69M 1.2B
Предишно отваряне	27.32
Предишно затваряне	26.69

Настроения в новините

By Acuity

50%

157 / 374 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Strong Bullish Evidence

23.91 / 25.04 Подкрепа & съпротива

Amphastar Pharmaceuticals Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

31.12.2025 г., 22:20 ч. UTC

Значими двигатели на пазара

Outlook Therapeutics Shares Fall After Another FDA Rejection of Macular Degeneration Drug

31.12.2025 г., 17:31 ч. UTC

Значими двигатели на пазара

OwlTing Climbs on Launch of $10 Million Stock-Buyback Program

31.12.2025 г., 16:30 ч. UTC

Значими двигатели на пазара

Trump Media Gains on Plan to Distribute Digital Tokens to Shareholders

31.12.2025 г., 15:19 ч. UTC

Значими двигатели на пазара

Axsome Shares Climb on FDA Fast‑Track for Alzheimer's Drug, Backing for Narcolepsy Filing

31.12.2025 г., 15:17 ч. UTC

Значими двигатели на пазара

Nike Shares Rise After CEO Hill Buys $1 Million of Shares

31.12.2025 г., 14:37 ч. UTC

Значими двигатели на пазара

Corcept Shares Fall as FDA Requires More Evidence for Hypercortisolism Drug Application

31.12.2025 г., 21:50 ч. UTC

Пазарно говорене

Basic Materials Roundup: Market Talk

31.12.2025 г., 21:13 ч. UTC

Придобивния, сливания и поглъщания

10 People to Watch in Wealth Management in 2026 -- Barrons.com

31.12.2025 г., 20:40 ч. UTC

Пазарно говорене

Dollar Posting Its Worst Year Since 2017 -- Market Talk

31.12.2025 г., 20:22 ч. UTC

Пазарно говорене

Oil Posts Loss in a Year Marked By Plentiful Supply -- Market Talk

31.12.2025 г., 19:50 ч. UTC

Пазарно говорене

U.S. Natural Gas Futures Sink on Weather Outlook -- Market Talk

31.12.2025 г., 19:31 ч. UTC

Пазарно говорене

Precious Metals Cap Off Record Runs -- Market Talk

31.12.2025 г., 18:50 ч. UTC

Пазарно говорене

Global Equities Roundup: Market Talk

31.12.2025 г., 18:50 ч. UTC

Пазарно говорене

Canadian Gold Miners Enjoy a Bumper Year in 2025 -- Market Talk

31.12.2025 г., 17:17 ч. UTC

Пазарно говорене

U.S. Natural Gas Inventories Fall Less Than Expected -- Market Talk

31.12.2025 г., 17:16 ч. UTC

Значими двигатели на пазара

OwlTing Climbs on Launch of $10M Stock-Buyback Program

31.12.2025 г., 17:15 ч. UTC

Пазарно говорене

Global Commodities Roundup: Market Talk

31.12.2025 г., 17:00 ч. UTC

Придобивния, сливания и поглъщания

Nvidia Is Getting Creative as Options to Use Its Cash Flood Narrow -- Heard on the Street -- WSJ

31.12.2025 г., 15:57 ч. UTC

Придобивния, сливания и поглъщания

Vanda Pharmaceuticals Shares Jump 30% on Motion Sickness Drug Approval -- Barrons.com

31.12.2025 г., 15:54 ч. UTC

Пазарно говорене

Layoff Data Supports Dollar at End of Losing Year -- Market Talk

31.12.2025 г., 15:02 ч. UTC

Значими двигатели на пазара

Nike Shares Rise After CEO Hill Buys $1M of Shares

31.12.2025 г., 14:40 ч. UTC

Придобивния, сливания и поглъщания

Nike CEO Buys $1 Million of Stock as Insiders Bet on a Turnaround -- Barrons.com

31.12.2025 г., 14:20 ч. UTC

Пазарно говорене

Crude Futures On Track to End the Year With Losses -- Market Talk

31.12.2025 г., 13:46 ч. UTC

Пазарно говорене

U.S. Natural Gas Falls on Milder Weather Outlook -- Market Talk

31.12.2025 г., 13:01 ч. UTC

Печалби

Придобивния, сливания и поглъщания

Charles Schwab Is Back on Offense. Its Stock Is a Buy. -- Barrons.com

31.12.2025 г., 11:10 ч. UTC

Пазарно говорене

Copper Remains in Touching Distance of Record Highs -- Market Talk

31.12.2025 г., 10:46 ч. UTC

Пазарно говорене

Euro on Track For Strong Annual Performance -- Market Talk

31.12.2025 г., 10:25 ч. UTC

Пазарно говорене

European Gas Prices Rise But Remain on Track for Heavy Annual Loss -- Market Talk

31.12.2025 г., 10:23 ч. UTC

Пазарно говорене

Chinese Yuan Rises to 31-Month High Against Dollar as Policymakers -- Market Talk

31.12.2025 г., 09:33 ч. UTC

Пазарно говорене

Dollar Set For Worst Annual Performance Since 2017 -- Market Talk

Сравнение с други в отрасъла

Ценова промяна

Amphastar Pharmaceuticals Inc Прогноза

Ценова цел

By TipRanks

13.89% нагоре

12-месечна прогноза

Среден 30.75 USD 13.89%

Висок 34 USD

Нисък 25 USD

Според 5 анализатори от Wall Street, предложили 12-месечна ценова цел за Amphastar Pharmaceuticals Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Купи

5 ratings

Купи

Задържане

Продай

Според 5 анализатори, дали борсови рейтинги на Amphastar Pharmaceuticals Inc през последните 3 месеца.

Техническа оценка

By Trading Central

23.91 / 25.04Подкрепа & съпротива

Recent bullish events outweigh bearish events.

All events are bearish.

Настроение

By Acuity

157 / 374 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Amphastar Pharmaceuticals Inc

Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency. The company provides Amphadase, an injection to absorb and disperse other injected drugs; Epinephrine injection for allergic reactions; Lidocaine jelly, an anesthetic product for urological procedures; Lidocaine topical solution for various procedures; Phytonadione injection, a vitamin K1 injection for newborn babies; emergency syringe products; morphine injection for use with patient-controlled analgesia pumps; and Lorazepam injection for surgery and medical procedures. In addition, it offers Neostigmine methylsulfate injection to treat myasthenia gravis and to reverse the effects of muscle relaxants; Isoproterenol hydrochloride injection for mild or transient episodes of heart block; Ganirelix Acetate injection for the inhibition of premature luteinizing hormone surges; Vasopressin to increase blood pressure; and Regadenoson, a stress agent for radionuclide myocardial perfusion imaging. Further, the company distributes recombinant human insulin APIs and porcine insulin API. Additionally, it develops generic product candidates, such as injectable, inhalation, and analytical technologies; biosimial product candidates; and intranasal epinephrine for the treatment of allergic reactions. The company was founded in 1996 and is headquartered in Rancho Cucamonga, California.